Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Tonix Pharm Holdings (TNXP)

Tonix Pharm Holdings (TNXP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 47,845
  • Shares Outstanding, K 186,894
  • Annual Sales, $ 7,770 K
  • Annual Income, $ -116,660 K
  • EBIT $ -142 M
  • EBITDA $ -137 M
  • 60-Month Beta 2.02
  • Price/Sales 0.39
  • Price/Cash Flow N/A
  • Price/Book 0.54
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -52.74
  • Most Recent Earnings $-0.23 on 11/12/24
  • Next Earnings Date 11/14/24
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -1.79
  • Number of Estimates 2
  • High Estimate -0.13
  • Low Estimate -3.45
  • Prior Year -27.48
  • Growth Rate Est. (year over year) +93.49%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.1906 +39.61%
on 12/11/24
1.3000 -79.53%
on 12/17/24
+0.0695 (+35.35%)
since 12/10/24
3-Month
0.1264 +110.52%
on 11/18/24
1.3000 -79.53%
on 12/17/24
+0.1257 (+89.53%)
since 10/10/24
52-Week
0.1180 +125.51%
on 10/03/24
12.4800 -97.87%
on 02/20/24
-9.5643 (-97.29%)
since 01/10/24

Most Recent Stories

More News
Tonix Pharmaceuticals Further Strengthens Commercial Leadership Team with Appointment of Gary Ainsworth as Vice President of Market Access

TNXP : 0.2721 (+6.29%)
Tonix Pharmaceuticals to Present at Two Upcoming January Investor Conferences

TNXP : 0.2721 (+6.29%)
Top 5 Biotech Stocks Dominating Retail Investor Conversations In 2024

From Tonix Pharmaceuticals’ progress on fibromyalgia treatments to Nvidia-backed Recursion Pharmaceuticals, these stocks sparked significant message volume growth on Stocktwits.

GALT : 1.1100 (-1.77%)
TNXP : 0.2721 (+6.29%)
CDIO : 0.7179 (-1.68%)
CADL : 8.45 (-3.21%)
RXRX : 6.89 (-5.10%)
Tonix Pharmaceuticals Announces PDUFA Goal Date of August 15, 2025, for FDA Decision on U.S. Marketing Approval for TNX-102 SL for Fibromyalgia

TNXP : 0.2721 (+6.29%)
Tonix Pharma Stock’s Retail Chatter Explodes After FDA Nod For New Drug Application

The drug already received Fast Track designation in July 2024, expediting the review process due to its potential to address an unmet medical need.

TNXP : 0.2721 (+6.29%)
Tonix Pharmaceuticals Announces FDA Acceptance of the New Drug Application (NDA) for TNX-102 SL for Fibromyalgia

TNXP : 0.2721 (+6.29%)
Tonix's TNX 102-SL Could Offer New Hope of Pain Relief Without Narcotics for Fibromyalgia Sufferers

This post was written and published as a collaboration between the in-house editorial team at Benzinga and Tonix Pharmaceuticals Holding Corp. with financial support from Tonix. The two organizations work...

TNXP : 0.2721 (+6.29%)
Tonix Pharmaceuticals Announces Appointment of New Executives to Support Upcoming TNX-102 SL Launch for Fibromyalgia Management

Tonix Pharmaceuticals hires Bradley Raudabaugh and Errol Gould to enhance marketing and medical affairs ahead of TNX-102 SL FDA review.Quiver AI SummaryTonix Pharmaceuticals has announced the appointment...

TNXP : 0.2721 (+6.29%)
Tonix Pharmaceuticals Announces Expansion of Leadership Team with Two Strategic Hires

TNXP : 0.2721 (+6.29%)
Tonix Pharmaceuticals to Present at NobleCon20 Annual Emerging Growth Equity Conference

Tonix Pharmaceuticals will present at NobleCon20 and conduct investor meetings in December 2024 in Boca Raton, Florida.Quiver AI SummaryTonix Pharmaceuticals Holding Corp. announced that Jessica Morris,...

TNXP : 0.2721 (+6.29%)

Business Summary

Tonix Pharmaceuticals Holding Corp. is a specialty pharmaceutical company focused on developing new pharmaceutical products for CNS conditions. The Company develops therapies for disorders that include fibromyalgia syndrome and post-traumatic stress disorder. Its lead product candidates include TNX-102,...

See More

Key Turning Points

3rd Resistance Point 0.3410
2nd Resistance Point 0.3240
1st Resistance Point 0.2900
Last Price 0.2721
1st Support Level 0.2390
2nd Support Level 0.2220
3rd Support Level 0.1880

See More

52-Week High 12.4800
Fibonacci 61.8% 7.7577
Fibonacci 50% 6.2990
Fibonacci 38.2% 4.8403
Last Price 0.2721
52-Week Low 0.1180

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar